UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
UCB→Neurona Therapeutics
Apr 17, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Avista Healthcare Partners acquired Bentec Medical from Greyrock Capital Group and Hermitage Equity Partners to strengthen its medical device manufacturing presence. Bentec, founded in 1994 and headquartered in Woodland, California, specializes in complex silicone components for medical device OEMs and a portfolio of proprietary medical devices used by healthcare providers.
Bentec’s products serve ENT, oncology, aesthetics, biliary surgery, and neonatal care. Avista plans to support Bentec’s next phase of growth by investing in innovation, expanding manufacturing capacity, expanding geographically, and pursuing potential strategic acquisitions.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
UCB→Neurona Therapeutics
Apr 17, 2026
Jackson Memorial Hospital
Apr 17, 2026
Kailera Therapeutics
Apr 17, 2026
Gilead→Arcellx
Apr 17, 2026
Panthera Biopartners→OEC
Apr 17, 2026